Breast Cancer
Inhibiton Therapeutics Provides Update for ICA-1 Compound in-Vitro Testing in Breast Cancer Cell Lines
Published in Cancer Weekly, January 29th, 2008
Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran's Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.
Previously announced laboratory testing has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells finding that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-01-29)
More Articles from Cancer Weekly
- Adenoma
Researchers from Kumamoto University detail findings in adenoma - Breast Cancer
Celsion to Proceed with Phase II Pivotal Breast Cancer Trial after Receiving Supportive FDA Response - Cancer Gene Therapy
New cancer gene therapy study results reported from H.L. Oian et al - Cancer Gene Therapy
Reports outline cancer gene therapy study results from Tohoku University, Medical Department - Cancer Vaccines
Reports from P. Nanni and co-researchers add new data to research in cancer vaccines - Cancer Vaccines
Studies from Sichuan University yield new information about cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
